EXAS

EXAS is trading as a high-conviction M&A arbitrage play rather than a fundamental growth story. The 'Ground Truth' driving the 2.0x volume is today's expiration of the Hart-Scott-Rodino (HSR) antitrust waiting period, effectively clearing the regulatory path for Abbott's (ABT) $21B acquisition at $105/share. While the broader RISK_ON regime is chasing AI infrastructure, EXAS is decoupled, pinned just below the deal price as arb desks absorb the spread. The technical 'Perfect Stack' signals are simply reflecting the deal's increasing certainty, insulating the stock from today's negative news regarding patent invalidations by Geneoscopy.